Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 107.49% | 104.84% | 108.27% | 113.00% | -2,033.69% |
| Total Depreciation and Amortization | 64.47% | 81.44% | 35.08% | 39.95% | 51.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.59% | -93.74% | -94.21% | -94.48% | 515.86% |
| Change in Net Operating Assets | -48.54% | -60.53% | -676.24% | -236.70% | -2,262.89% |
| Cash from Operations | 56.52% | -88.88% | -136.24% | -114.06% | -88.66% |
| Capital Expenditure | 79.15% | 83.19% | 68.51% | 72.82% | 41.94% |
| Sale of Property, Plant, and Equipment | -63.49% | -80.95% | -50.70% | -39.61% | -13.48% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.60% | 76.06% | 50.70% | -6.94% | -17.15% |
| Cash from Investing | 73.85% | 72.05% | 44.67% | -0.63% | 25.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,956.47% | 2,815.54% | 423.56% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -997.04% | -1,764.71% | -- | -- | -1,452.00% |
| Cash from Financing | 587.85% | 653.86% | -11.72% | -15.92% | 2,980.44% |
| Foreign Exchange rate Adjustments | -118.31% | -117.99% | 67.46% | 8.39% | 114.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 340.24% | 367.32% | -998.23% | -360.33% | -477.43% |